Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint inhibitors targeting PD-L1/PD-1 are crucial cancer therapies.
• PD-L1/PD-1 interaction suppresses T cell activity, facilitating tumor immune evasion.
• Current response rates for PD-L1/PD-1 blockade in solid tumors are suboptimal.

Purpose of the Study:

• To provide a comprehensive review of PD-L1 expression regulation.
• To identify molecular mechanisms underlying PD-L1 deregulation.
• To highlight advancements and limitations in PD-L1-targeted immunotherapy.

Main Methods:

• Literature review of recent research on PD-L1 regulation.
• Analysis of structural characteristics, genomic alterations, and epigenetic modifications of PD-L1.
• Examination of signaling pathways, microRNA regulation, and post-translational modifications impacting PD-L1 expression.

Main Results:

• PD-L1 expression is regulated by diverse mechanisms including genomic, epigenetic, and signaling pathways.
• Inflammatory and oncogenic signaling pathways significantly influence PD-L1 levels.
• MicroRNA and post-translational modifications further modulate PD-L1 function and expression.

Conclusions:

• Understanding PD-L1 regulation is essential for enhancing PD-L1/PD-1 blockade therapy efficacy.
• Further research into PD-L1 regulatory mechanisms can reveal novel immunotherapy targets.
• Optimizing PD-L1-targeted strategies requires addressing current clinical limitations.